EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?

Eleftherios Chatzimichail iD, Kristina Pfau, Zisis Gatzioufas, Georgios D Panos iD

Drug Design, Development and Therapy · 2024

DOI: 10.2147/dddt.s457303 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Eleftherios Chatzimichail und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Diabetic Retinopathy, Macular Edema, Wet Macular Degeneration. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsDiabetic RetinopathyMacular EdemaWet Macular DegenerationInfant, NewbornHumansRanibizumabVascular Endothelial Growth Factor AAngiogenesis InhibitorsCost-Benefit AnalysisVisual AcuityAntibodies, Monoclonal, HumanizedIntravitreal InjectionsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

age-related macular degenerationbiosimilarscost-effectivenessdiabetic macular edemaranibizumabretinal disordersretinal vein occlusion

Substanzen

RanibizumabBiosimilar PharmaceuticalsVascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Ophthalmology, University Hospital of Basel, Basel, Switzerland.
  • Department of Ophthalmology, University Hospital Bonn, Bonn, Germany.
  • Department of Ophthalmology, Queen's Medical Centre, Nottingham University Hospitals, Nottingham, UK.
  • Division of Ophthalmology and Visual Sciences, School of Medicine, University of Nottingham, Nottingham, UK.

ORCID-Profile: Eleftherios Chatzimichail, Georgios D Panos

Zitieren

APA

Chatzimichail, E., Pfau, K., Gatzioufas, Z., & Panos, G. D. (2024). Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s457303

Vancouver

Chatzimichail E, Pfau K, Gatzioufas Z, Panos GD. Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s457303

BibTeX
@article{Chatzimichail2024,
  author = {Chatzimichail, Eleftherios and Pfau, Kristina and Gatzioufas, Zisis and Panos, Georgios D},
  title = {Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  doi = {10.2147/dddt.s457303}
}
Kostenlos starten →